

Eversight and Subsidiary

Financial Statements

**December 31, 2020
(With Summarized Comparative
Information for 2019)**



Table of Contents

	Page
Independent Auditors' Report	1
Basic Financial Statements	
Consolidated Statement of Financial Position	3
Consolidated Statement of Activities	4
Consolidated Statement of Functional Expenses	5
Consolidated Statement of Cash Flows	6
Notes to the Consolidated Financial Statements	7
Supplementary Information	
Consolidating Statement of Financial Position	24
Consolidating Statement of Activities	25

Independent Auditors' Report

Management and the Board of Directors
Eversight and Subsidiary
Ann Arbor, Michigan

We have audited the accompanying consolidated financial statements of Eversight and Subsidiary which comprise the consolidated statement of financial position as of December 31, 2020, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related consolidated notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Eversight and Subsidiary as of December 31, 2020, and the consolidated changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information

We have previously audited Eversight and Subsidiary's December 31, 2019 consolidated financial statements, and our report dated May 29, 2020 expressed an unmodified opinion on those consolidated financial statements. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2019 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Report on Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating statement of financial position and consolidating statement of activities is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Yeo & Yeo, P.C.

Ann Arbor, Michigan
May 3, 2021

Eversight and Subsidiary
Consolidated Statement of Financial Position
December 31, 2020
(With Summarized Comparative Information for 2019)

	<u>2020</u>	<u>2019</u>
Assets		
Current assets		
Cash and cash equivalents	\$ 4,936,437	\$ 3,511,158
Accounts receivables	3,404,738	2,941,990
Unconditional pledges to give	10,000	38,410
Prepaid expenses	86,040	54,512
Other assets	<u>-</u>	<u>9,557</u>
Total current assets	8,437,215	6,555,627
Deposits	182,173	173,121
Unconditional pledges to give, net of current portion	10,000	10,000
Investments	9,470,354	6,765,972
Property and equipment, net	<u>7,590,869</u>	<u>9,551,040</u>
Total assets	<u>\$ 25,690,611</u>	<u>\$ 23,055,760</u>
Liabilities and Net Assets		
Current liabilities		
Accounts payable	\$ 668,758	\$ 849,423
Deferred revenue	9,897	-
Current portion of notes payable	2,246,600	155,000
Capital lease obligation, current portion	340,861	190,502
Accrued liabilities	<u>1,118,633</u>	<u>1,288,005</u>
Total current liabilities	4,384,749	2,482,930
Long-term notes payable, net of current portion	-	194,000
Capital lease obligation, net of current portion	6,760,652	7,101,391
Deferred rent	<u>34,333</u>	<u>55,485</u>
Total liabilities	<u>11,179,734</u>	<u>9,833,806</u>
Net assets		
Without donor restrictions		
Undesignated	4,459,467	5,209,332
Board designated capital reserve	474,711	500,000
Board designated endowments	87,134	87,134
Board designated scholarships	100,000	100,000
Board designated investment fund	<u>9,191,266</u>	<u>7,075,016</u>
Total without donor restrictions	<u>14,312,578</u>	<u>12,971,482</u>
With donor restrictions		
Perpetual in nature	91,953	91,953
Purpose restrictions	<u>106,346</u>	<u>158,519</u>
Total with donor restrictions	<u>198,299</u>	<u>250,472</u>
Total net assets	<u>14,510,877</u>	<u>13,221,954</u>
Total liabilities and net assets	<u>\$ 25,690,611</u>	<u>\$ 23,055,760</u>

See Accompanying Notes to the Consolidated Financial Statements

Eversight and Subsidiary
Consolidated Statement of Activities
For the Year Ended December 31, 2020
(With Summarized Comparative Totals for 2019)

	Without Donor Restrictions	With Donor Restrictions	Total	
			2020	2019
Public support and program revenues				
Public support				
Contributions	\$ 654,413	\$ 51,800	\$ 706,213	\$ 1,182,481
Program revenues				
Eye tissue processing fees	20,377,388	-	20,377,388	22,042,406
Other revenue	92,086	-	92,086	35,028
Total program revenues	20,469,474	-	20,469,474	22,077,434
Net assets released from restrictions	103,973	(103,973)	-	-
Total public support and program revenues	21,227,860	(52,173)	21,175,687	23,259,915
Expenses				
Program services				
Tissue procurement and processing program	14,652,659	-	14,652,659	15,900,802
Education program	138,367	-	138,367	226,196
Research program	1,061,085	-	1,061,085	1,249,474
Total program services	15,852,111	-	15,852,111	17,376,472
Support services				
Administration	4,387,740	-	4,387,740	4,003,429
Fundraising	648,007	-	648,007	947,330
Total support services	5,035,747	-	5,035,747	4,950,759
Total expenses	20,887,858	-	20,887,858	22,327,231
Public support and program revenues over (under) expenses	340,002	(52,173)	287,829	932,684
Nonoperating income				
Net investment earnings	1,001,094	-	1,001,094	987,073
Change in net assets	1,341,096	(52,173)	1,288,923	1,919,757
Net assets - beginning of year	12,971,482	250,472	13,221,954	11,302,197
Net assets - end of year	\$ 14,312,578	\$ 198,299	\$ 14,510,877	\$ 13,221,954

See Accompanying Notes to the Consolidated Financial Statements

Eversight and Subsidiary
Consolidated Statement of Functional Expenses
For the Year Ended December 31, 2020
(With Summarized Comparative Totals for 2019)

	Program Services Expenses				Supporting Services Expenses			Total	
	Tissue Program	Education Program	Research Program	Total Program Services	Administration	Fundraising	Total Supporting Services	2020	2019
Functional Expenses									
Salaries and related expenses	\$ 7,040,253	\$ 92,897	\$ 608,444	\$ 7,741,594	\$ 3,333,287	\$ 504,977	\$ 3,838,264	\$ 11,579,858	\$ 12,079,397
Clinical lab and technical fees	5,590,943	-	156,117	5,747,060	-	-	-	5,747,060	5,931,157
Public and professional education	39,023	28,858	3,574	71,455	-	3,574	3,574	75,029	133,774
Research grants and awards	-	-	94,735	94,735	-	-	-	94,735	104,724
Business development	12,514	-	(2,847)	9,667	10,608	383	10,991	20,658	350,113
Conferences and meetings	10,738	181	734	11,653	22,050	45,031	67,081	78,734	116,071
Travel	37,029	444	2,669	40,142	15,009	2,394	17,403	57,545	167,150
Bad debt expense	26,169	-	-	26,169	-	-	-	26,169	11,500
Depreciation	468,875	3,820	53,482	526,177	153,400	26,741	180,141	706,318	667,123
Professional fees	131,499	-	7,309	138,808	198,771	-	198,771	337,579	441,374
Rent and utilities	612,136	4,969	70,797	687,902	199,954	34,788	234,742	922,644	1,101,767
Tax expense	-	-	-	-	-	-	-	-	68
Insurance	98,074	784	10,972	109,830	31,550	5,486	37,036	146,866	149,301
Supplies	18,830	163	1,855	20,848	5,657	1,143	6,800	27,648	44,569
Membership dues	156,471	-	-	156,471	-	-	-	156,471	176,167
Postage and shipping	8,081	152	805	9,038	4,385	1,061	5,446	14,484	19,262
Interest and finance charges	130,583	1,097	15,363	147,043	44,887	7,681	52,568	199,611	81,090
Printing and publications	5,781	2,890	2,890	11,561	-	-	-	11,561	26,995
Equipment rental and maintenance	156,041	1,218	17,055	174,314	49,189	8,527	57,716	232,030	277,954
Licenses and registrations	108,105	874	12,543	121,522	35,652	6,119	41,771	163,293	154,573
Miscellaneous	1,514	20	4,588	6,122	283,341	102	283,443	289,565	293,102
Total	\$ 14,652,659	\$ 138,367	\$ 1,061,085	\$ 15,852,111	\$ 4,387,740	\$ 648,007	\$ 5,035,747	\$ 20,887,858	\$ 22,327,231

See Accompanying Notes to the Consolidated Financial Statements

Eversight and Subsidiary
Consolidated Statement of Cash Flows
For the Year Ended December 31, 2020
(With Summarized Comparative Information for 2019)

	<u>2020</u>	<u>2019</u>
Cash flows from operating activities		
Change in net assets	\$ 1,288,923	\$ 1,919,757
Items not requiring cash		
Depreciation	706,318	667,123
Bad debt expense	26,169	11,500
(Gain) loss on disposal of equipment	(104,105)	25,700
Deferred rent	(21,152)	(42,041)
Realized and unrealized gain on investment	(922,534)	(804,892)
Changes in operating assets and liabilities		
Accounts receivables	(488,917)	(291,326)
Unconditional pledges to give	28,410	(11,235)
Prepaid expenses	(31,528)	6,299
Other assets	9,557	4,410
Deposits	(9,052)	159,424
Accounts payable	(180,665)	27,089
Deferred revenue	9,897	-
Accrued liabilities	(169,372)	(110,015)
Net cash provided by operating activities	<u>141,949</u>	<u>1,561,793</u>
Cash flows from investing activities		
Purchase of property and equipment	(96,626)	(730,299)
Proceeds from sale of property and equipment	1,454,705	12,000
Purchase of investments	(6,273,364)	(184,080)
Proceeds from sale of investments	<u>4,491,516</u>	<u>700,001</u>
Net cash used by investing activities	<u>(423,769)</u>	<u>(202,378)</u>
Cash flows from financing activities		
PPP loan proceeds	2,246,600	-
Repayments of long-term debt	(349,000)	(148,500)
Payments on capital lease obligations	<u>(190,501)</u>	<u>(47,156)</u>
Net cash provided (used) by financing activities	<u>1,707,099</u>	<u>(195,656)</u>
Change in cash and cash equivalents	<u>1,425,279</u>	<u>1,163,759</u>
Cash and cash equivalents - beginning of year	<u>3,511,158</u>	<u>2,347,399</u>
Cash and cash equivalents - end of year	<u>\$ 4,936,437</u>	<u>\$ 3,511,158</u>
Supplemental information		
Cash paid during the year for interest	<u>\$ 199,611</u>	<u>\$ 81,090</u>
Supplemental schedule of non-cash investing and financing activities		
Assets acquired through capital leases	<u>\$ -</u>	<u>\$ 7,339,049</u>

See Accompanying Notes to the Consolidated Financial Statements

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 1 - Organization

Established in 1947, Eversight is a network of community-based eye banks based in Ann Arbor, Michigan, that serves as the nation's largest nonprofit provider of donated tissue for sight-restoring corneal transplants in the United States. Its mission is to restore sight and prevent blindness through the healing power of donation, transplantation, and research. Operating 24/7/365 from locations in Connecticut, Illinois, Michigan, New Jersey, Ohio and South Korea, Eversight is responsible for recovering, evaluating and providing human eye tissue for transplantation; supporting research into the causes and cures of blinding eye conditions; promoting donation awareness through public and professional education; and providing humanitarian aid to people around the world in need of corneal transplantation.

Through its U.S. and international initiatives, working closely with donor families and surgeons, Eversight recovers, prepares, and provides donate eye/corneal tissue to ensure the gift of sight for more than 8,000 corneal transplant patients each year. Tissue services are provided at low or no cost for patients who cannot afford transplant surgeries and for surgeons conducting medical mission trips worldwide. Charitable donations to Eversight's Gift of Sight Fund provide financial aid to individuals who cannot afford the cost of a cornea transplant and supports humanitarian efforts to cure blindness. To date, Eversight has fulfilled 100 percent of charitable care requests submitted by surgeons on behalf of their patients.

In the pursuit to eliminate blinding eye diseases, Eversight established the Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, to provide leading ophthalmology researchers with needed resources to find cures and treatments for eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Capabilities and services include developing eye banking practices that expand the availability of eye tissue for critical studies requiring specific types of tissue to gain new knowledge for future treatment and cures; procuring, processing and preserving critically needed corneal and non-corneal tissue; performing fluorescence, bright field and phase-contrast microscopy; and providing molecular biology and RNA isolation service lines for research partners, as well as services utilizing crucial R&D instrumentation. Research and clinical leadership and staff are highly involved primary and co-investigators on new research.

Since 1980, the Eversight Eye & Vision Research Grant Program has supported researchers at leading academic medical institutions including Harvard, Tufts, Cleveland Clinic, Case Western Reserve, University of Michigan and Northwestern. Eversight's grant program provides critical, early-stage funding or seed grants that are intended to drive foundational research and discovery. Many of these projects have stimulated larger-scale studies and won further financial support from the National Institutes of Health.

Eversight is one of the few nonprofit eye bank networks with the expertise, cultural competence, and philanthropic support to help developing countries establish their own sustainable eye banking infrastructures in regions where millions suffer from treatable blindness. In 2015, Eversight International was formed as a 501(c)3 nonprofit organization to build on this work with medical professionals and government entities in China, the Middle East, Pakistan, and South Korea. Through these partnerships, Eversight International establishes local donation programs and conducts technical laboratory training so tissue can be recovered, processed, and distributed safely, increasing access to corneal transplants and the availability of eye tissue for research and education purposes.

In 2019, Eversight earned GuideStar's Platinum Seal of Transparency for communicating its work and the progress toward its mission. Eversight maintains its commitment to excellence as an accredited member of the Eye Bank Association of America (EBAA) and by meeting the highest quality standards set by the U.S. Food and Drug Administration. It and collaborates with surgeons, researchers, academic medical centers, and eye banks across the United States and abroad.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Eversight actively and consistently monitors and measures the success of all programs and operations. Leadership, staff, and the Board of Directors closely monitor a dashboard of key performance and financial indicators to ensure and drive progress. Key performance indicators include tissue and research placements; expenses and revenue; and quality performance metrics recoveries. Multiple additional metrics and data are monitored at operational, research and departmental levels to ensure quality, responsiveness and impact including measures of fulfillment, precision, quality, compliance, surgeon satisfaction and outcomes and to inform continuous evaluation to improve our impact, performance and outcomes with particular emphasis on clinical operations, training and quality improvement.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net assets without donor restrictions – Net assets available for use in general operations and not subject to donor (or certain grantor) restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net assets with donor restrictions – Net assets subject to donor (or certain grantor) imposed restrictions. Some donor imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity.

The Organization reports contributions restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor restricted contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

Principles of Consolidation

The 2020 consolidated financial statements include the financial information of Eversight and Eversight International. All inter-entity balances and transactions have been eliminated.

Cash and Cash Equivalents

For the purpose of the Statement of Cash Flows, the Organization considers as cash and cash equivalents all highly liquid investments, which can be converted into known amounts of cash and have a maturity period of ninety days or less at the time of purchase.

The Organization maintains cash accounts at an area financial institution. The carrying amount of the Organization's deposits with financial institutions at year end was \$4,936,437. The actual bank balances amounted to \$5,194,708. Of these balances, \$4,944,708 was not insured by the Federal Deposit Insurance Corporation.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Revenue Recognition

All contributions are considered available for the Organization's general programs unless specifically restricted by the donor. Amounts received that are designated for future periods or purpose by the donor are reported as increases in net assets with donor restrictions. Contributions received with time or purpose restrictions that are met in the same reporting period are reported as support without donor restrictions. Investment income that is limited to specific uses by donor restrictions is reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the income is recognized.

Pledges receivable in the accompanying statement of financial position consist of unconditional promises to give, which are recorded at their net realizable value at the time the promises are received. These promises to give are reflected as either current or long-term receivables on the statement of financial position.

Eye tissue processing fees are recognized when eye tissue is shipped to the end customer and the performance obligation is met.

Charity Care

Eversight proudly fulfills 100 percent of charitable care requests in its communities with the Eversight Gift of Sight Program, ensuring individuals seeking cornea transplants receive treatment for their sight regardless of financial constraints. Patients are selected based on an analysis of financial information obtained from the patient. As the organization does not expect payment, the estimated charges for services are not included in net revenue. Tissue services are also offered at no cost to surgeons traveling abroad for medical mission trips to help people in parts of the world lacking access to adequate eye care. Total charitable care services for the years ended December 31, 2020 and 2019 was \$155,880 and \$218,550, respectively.

Accounts Receivable

The Organization's accounts receivable at December 31, 2020, consist of processing fees from various healthcare organizations for tissue. Accounts receivable are stated at net invoice amounts. An allowance for doubtful accounts is established based on a specific assessment of all invoices that remain unpaid following normal payment periods. All amounts deemed uncollectible are charged against the allowance for doubtful accounts in the period that determination is made.

For the year ended December 31, 2020 and 2019, approximately 4%, of the Organization's revenue was earned from eye processing fees from Vision Share. Also, as of December 31, 2020 and 2019, approximately 6% and 10% of accounts receivable was due from Vision Share, respectively.

Promises to Give

Contributions are recognized when the donor makes a promise to give to the Organization that is, in substance, unconditional.

The Organization uses the income approach to value unconditional promises to give, in the aggregate on an annual basis, under the fair value option.

Unconditional promises to give are stated net of an allowance for doubtful accounts. The allowance for doubtful accounts for pledges receivable was \$0 at December 31, 2020 and 2019, respectively.

Prepaid Expenses

Prepaid expenses represent amounts paid in advance for future expenses. All prepaid amounts are expected to be fully utilized.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Investments

Investments are stated at fair values based upon quoted market prices using prevailing financial market information as of December 31, 2020. Realized gains and losses represent the difference between the proceeds received and the cost of investments sold. Unrealized gains and losses represent the change in the market value of the investments during the year. Donated investments are reflected as contributions at their fair values at date of receipt. Investment income is reported net of direct investment expenses.

Property and Equipment

Property and equipment are recorded at cost and are being depreciated on a straight-line basis over their estimated useful lives. Costs of maintenance and repairs are charged to expense when incurred. Property and equipment with costs exceeding \$5,000 per single purchase or \$15,000 for group purchases will be capitalized. Leasehold improvements exceeding \$15,000 will be capitalized. The Organization reports gifts of property, plant, and equipment as unrestricted support unless explicit donor stipulations specify how the donated assets must be used.

Gifts of land, buildings, equipment, and other long-lived assets are also reported as revenue without donor restrictions and net assets, unless subject to time restrictions. Absent explicit donor stipulations for the time long-lived assets must be held, expirations of restrictions resulting in reclassification of net assets with donor restrictions as net assets without donor restrictions are reported when the long-lived assets are placed in service.

Functional Expenses

The costs of program and supporting services activities have been summarized on a functional basis in the consolidated statement of activities. The statement of functional expenses presents the natural classification detail of expenses by function. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Those expenses include salaries and benefits, depreciation and amortization, and occupancy. Salaries and benefits are allocated based on a time and cost review of where efforts are made, occupancy, depreciation and amortization are allocated based on a square footage basis.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, expenses, and other changes in net assets during the reporting period. Actual results could differ from those estimates.

Long-Lived Assets

The Organization evaluates long-lived assets for impairment using a discounted cash flow method whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with accounting principles generally accepted in the United States of America.

Federal Income Taxes

The Organization is a not-for-profit organization exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code and is exempt from similar state and local taxes. Although the Organization was granted income tax exemption by the Internal Revenue Service, such exemption does not apply to "unrelated business taxable income." Such income, pursuant to the Internal Revenue Code and related regulations, includes income derived from activities other than the normal day-to-day operations of the Organization. For the year ended December 31, 2020 there were no interest or penalties recorded or included in the financial statements related to tax liabilities.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Paycheck Protection Program (PPP) Loan

The Organization accounts for the PPP loan as a financial liability in accordance with FASB ASC 470 Debt. Interest is accrued throughout the life of the loan, even when no payments are currently due. The Organization has elected to recognize the entire liability as a current liability.

Subsequent Events

Management has evaluated subsequent events through May 3, 2021, which is the date the financial statements were available to be issued.

Note 3 - Liquidity and Availability

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

	<u>2020</u>	<u>2019</u>
Cash and cash equivalents	\$ 4,936,437	\$ 2,243,852
Investments	90,789	-
Accounts receivable	2,742,893	2,962,646
Promises to give	<u>-</u>	<u>48,410</u>
	<u>\$ 7,770,119</u>	<u>\$ 5,254,908</u>

The Organization's goal is generally to maintain financial assets to meet 30 days of operating expenses (approximately \$2 million). As part of its liquidity plan, excess cash is invested in short-term investments, including money market accounts and certificates of deposit.

The Organization's endowment funds consist of donor restricted endowments and funds designated by the board as endowments. Income from donor restricted endowments is restricted for specific purposes, with the exception of the amounts available for general use. Donor restricted endowment funds are not available for general expenditure.

The Organization's board-designated endowment of \$87,134 is subject to spending restriction as described in Note 7. Although the Organization does not intend to spend from this board-designated endowment (other than amounts appropriated for general expenditure as part of the Board's annual budget approval and appropriation), these amounts could be made available if necessary.

The Organization's board-designated investment fund consists of funds set aside at the Board's discretion for investing activities. These funds cannot be used for general expenditure without Board consent.

The Organization's board-designated capital reserve consists of funds set aside at the Board's discretion for future capital projects and additions. These funds cannot be used for general expenditure without Board consent.

The Organization has a \$1,000,000 line of credit available to meet cash flow needs.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 4 - Unconditional Pledges to Give

Unconditional pledges to give are scheduled to be collected as follows:

	2020	2019
Pledges due in less than one year	\$ 10,000	\$ 38,410
Pledges due in one to five years	10,000	10,000
Total unconditional pledges to give	20,000	48,410
Less allowance for doubtful pledges	-	-
Net unconditional pledges to give	<u>\$ 20,000</u>	<u>\$ 48,410</u>

Unconditional pledges to give activity for 2020 is detailed as follows:

Balance beginning of the year	\$ 48,410
Add new pledges	-
Less collections	28,410
Balance end of the year	<u>\$ 20,000</u>

Note 5 - Investments

Fair value of marketable debt and equity securities at December 31 consist of:

	2020	2019
Money market funds	\$ 1,574,861	\$ 146,130
Corporate and government bonds	3,033,166	3,767,841
Equities	4,844,118	2,831,345
Total	<u>\$ 9,452,145</u>	<u>\$ 6,745,316</u>

The net investment earnings included in the consolidated statement of activities are summarized as follows for the year ended December 31:

	2020	2019
Dividend and interest income	\$ 142,247	\$ 246,808
Investment fees	(63,687)	(64,627)
Unrealized gain	715,224	540,111
Realized gain	207,310	264,781
Total	<u>\$ 1,001,094</u>	<u>\$ 987,073</u>

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 6 - Property and Equipment

The cost of property and equipment of the Organization is summarized as follows:

	2020	2019
Land	\$ -	\$ 170,000
Construction in progress	25,289	-
Equipment and software	6,164,809	6,364,572
Furniture and fixtures	814,703	855,181
Leasehold improvements	2,064,640	2,469,996
Buildings	<u>7,339,131</u>	<u>9,036,757</u>
 Total cost	 16,408,572	 18,896,506
 Accumulated depreciation	 <u>(8,817,703)</u>	 <u>(9,345,466)</u>
 Property and equipment, net	 <u>\$ 7,590,869</u>	 <u>\$ 9,551,040</u>

Depreciation expense for the years ended December 31, 2020 and 2019 were \$706,318 and \$667,123, respectively.

Note 7 - Endowment Fund

The Organization's endowment consists of individual funds established to fulfill its mission statement. Its endowment includes net assets with donor restrictions. As required by accounting procedures generally accepted in the United States of America, net assets associated with endowment funds, including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of net assets with donor restrictions.

Interpretation of Relevant Law

The board of directors of the Organization has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the fair value of the original gift as of the date of the donor restricted endowment funds, unless there are explicit donor stipulations to the contrary. At December 31, 2020, there were no such donor stipulations. As a result of this interpretation, the Organization retains in perpetuity (a) the original value of initial and subsequent gift amounts donated to the Endowment and (b) any accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added. Donor restricted amounts not retained in perpetuity are subject to appropriation for expenditure by us in a manner consistent with the standard of prudence prescribed by UPMIFA. The Organization considers the following factors in making a determination to appropriate or accumulate donor restricted endowment funds: (1) The duration and preservation of the fund; (2) The purposes of the organization and the donor restricted endowment fund; (3) General economic conditions; (4) The possible effect of inflation and deflation; (5) The expected total return from income and the appreciation of investments; (6) Other *Investment Return Objectives, Risk Parameters and Strategies*. The Organization has adopted investment and spending policies, approved by the Board of Trustees, for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while also maintaining the purchasing power of those endowment assets over the long-term. Accordingly, the investment

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

process seeks to achieve an after-cost total real rate of return, including investment income as well as capital appreciation, which exceeds the annual distribution with acceptable levels of risk. Endowment assets are invested in a well-diversified asset mix, which includes equity and debt securities, that is intended to result in a consistent inflation-protected rate of return that has sufficient liquidity to make an annual distribution if chosen so by the Board of Trustees. Investment risk is measured in terms of the total endowment fund; investment assets and allocation between asset classes and strategies are managed to not expose the fund to unacceptable levels of risk.

Endowment net asset composition by type of fund as of December 31, 2020 is as follows:

	Without Donor Restriction	With Donor Restrictions	Total
Board-designated	\$ 87,134	\$ -	\$ 87,134
Donor-restricted			
Original donor-restricted gift amount and amounts required to be maintained in perpetuity by donor	-	91,953	91,953
	<u>\$ 87,134</u>	<u>\$ 91,953</u>	<u>\$ 179,087</u>

Changes in endowment net assets for the year ended December 31, 2020 were:

	Without Donor Restriction	With Donor Restrictions	Total
Beginning of year	\$ 87,134	\$ 91,953	\$ 179,087
Contributions	-	-	-
Distributions	-	-	-
Investment income	-	-	-
End of year	<u>\$ 87,134</u>	<u>\$ 91,953</u>	<u>\$ 179,087</u>

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Endowment net asset composition by type of fund as of December 31, 2019 is as follows:

	Without Donor Restriction	With Donor Restrictions	Total
Board-designated	\$ 87,134		\$ 87,134
Donor-restricted			
Original donor-restricted			
gift amount and amounts			
required to be maintained			
in perpetuity by donor	-	91,953	91,953
	<u>\$ 87,134</u>	<u>\$ 91,953</u>	<u>\$ 179,087</u>

Changes in endowment net assets for the year ended December 31, 2019 were:

	Without Donor Restriction	With Donor Restrictions	Total
Beginning of year	\$ 87,134	\$ 91,953	\$ 179,087
Contributions	-	-	-
Distributions	-	-	-
Investment income	-	-	-
End of year	<u>\$ 87,134</u>	<u>\$ 91,953</u>	<u>\$ 179,087</u>

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 8 - Notes Payable

During the fiscal year, the Organization received a Paycheck Protection Program (PPP) Loan of \$2,246,600 funded by the Federal government through the Small Business Administration. The loan is payable in monthly installments of \$126,432 over a 24-month period at 1% interest. The PPP loan and any accrued interest are forgivable after twenty-four weeks as long as the borrower meets certain criteria. The loan proceeds must be used for eligible purposes, including payroll, health insurance, retirement plans, state and local taxes assessed on employee compensation, mortgage interest, rent, and utilities. The criteria also reduces loan forgiveness for certain reductions in salaries or reductions in FTEs. When final forgiveness, if any, is determined, a gain on extinguishment of debt will be realized for any forgiven amounts. There is a deferral of payments until loan forgiveness is determined or 10 months after the last day of the covered period, whichever occurs first. The Organization anticipates complete forgiveness of the loan.

	<u>2020</u>	<u>2019</u>
The Organization has a note payable to National City Bank. The original note amount of \$2,550,000 is payable for a term of 15 years at 4.52 percent interest with monthly payments being paid on accrued interest with the final payment due February 1, 2022. This note is secured by the real estate mortgage on the property.	\$ -	\$ 349,000
Paycheck Protection Program (PPP) loan payable to PNC Bank, dated April 25, 2020 for the original amount of \$2,246,600. Payable in monthly installments of \$126,432, including interest at 1% per annum. Secured by all assets of the Organization. Matures April 25, 2022.	<u>2,246,600</u>	<u>-</u>
	2,246,600	349,000
Less current portion	<u>(2,246,600)</u>	<u>(155,000)</u>
Long-term debt, net of current portion	<u>\$ -</u>	<u>\$ 194,000</u>

Interest expense on notes payable was \$994 and \$4,411 for the years ended December 31, 2020 and 2019, respectively.

Note 9 - Line of Credit

The Organization has an unsecured line of credit arrangement totaling \$1,000,000. This arrangement provides for borrowing amounts for short-term use at prime plus 2%. While the line of credit was available for use, there were no borrowings during the year.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 10 - Capital Lease

The Organization leases an office under a capital lease expiring in 2034. The assets and liabilities under capital leases are recorded at the present value of the minimum lease payments for the fair value of the asset. The assets are depreciated over their estimated productive lives. Amortization of assets under capital leases is included in depreciation expense.

The following is a summary of property held under the capital lease:

	<u>2020</u>	<u>2019</u>
Building	\$ 7,339,049	\$ 7,339,049
Accumulated amortization	<u>(693,132)</u>	<u>(203,704)</u>
Total property held under capital leases	<u>\$ 6,645,917</u>	<u>\$ 7,135,345</u>

Minimum future lease payments under capital leases as of December 31, 2020, were as follows:

	<u>Principal</u>	<u>Interest</u>	<u>Total</u>
2021	\$ 340,861	\$ 191,050	\$ 531,911
2022	365,030	181,375	546,405
2023	390,524	171,017	561,541
2024	416,871	159,949	576,820
2025	444,531	148,140	592,671
Thereafter	<u>5,143,696</u>	<u>663,280</u>	<u>5,806,976</u>
Total capital lease obligation	<u>\$ 7,101,513</u>	<u>\$ 1,514,811</u>	<u>\$ 8,616,324</u>

The interest rate on the capitalized lease is 2.75% and is imputed based on the lower of the Organization incremental borrowing rate at the inception of each lease of the lessor's implicit rate of return.

Note 11 - Board-designated Funds

The board has designated certain funds for specific purposes and projects. The board has designated amounts in the Investment Fund to be invested for future use by the Organization. Board-designated amounts in the Investment Fund totaled \$9,191,266 and \$7,075,016 at December 31, 2020 and 2019, respectively. The investment fund is comprised of investments and interest receivable. Additionally, \$474,711 and \$500,000 of net assets were designated to purchase capital assets, \$87,134 and \$87,134 of net assets were designated for endowments and \$100,000 and \$100,000 of net assets were designated for scholarships at December 31, 2020 and 2019, respectively.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 12 - Revenue from Contracts with Customers

The following summarizes revenue by type for the year ended December 31:

	<u>2020</u>	<u>2019</u>
Revenue from contracts with customers	\$ 20,377,388	\$ 22,042,406
Contribution revenue	706,213	1,182,481
Net investment earnings	1,001,094	987,073
Other revenue	<u>92,086</u>	<u>35,028</u>
Total revenue	<u>\$ 22,176,781</u>	<u>\$ 24,246,988</u>

The following summarizes bad debt expense for the year ended December 31:

	<u>2020</u>	<u>2019</u>
Impairment loss on receivables and contract assets on contracts with customers	<u>\$ 26,169</u>	<u>\$ 11,500</u>

The revenue from contracts with customers for the year ended December 31 consists of:

	<u>2020</u>	<u>2019</u>
Revenue earned at a point in time	<u>\$ 20,377,388</u>	<u>\$ 22,042,406</u>

Revenue earned at a point in time consists of tissue processing fees provided to researchers and transplant professionals. The tissues are unique orders that are derived from the research or transplant needs and therefore the performance obligation is satisfied when the order is fulfilled; if the tissue is compromised, revenue is still earned as long as the tissue is shipped adhering to the terms of the contract. This is because the tissue use is unique to the needs of the research or transplant. There is no variable consideration for the tissue processing. The transaction price is determined by the terms of the contract. Because the majority of customers are regular and known for paying timely, there is no constraint.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

The following summarizes contract assets and contract liabilities as of:

	<u>January 1, 2019</u>	<u>December 31, 2019</u>	<u>December 31, 2020</u>
Accounts receivable	<u>\$ 2,662,164</u>	<u>\$ 2,941,990</u>	<u>\$ 3,404,738</u>
Deferred revenue	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 9,897</u>

There were no changes in judgments related to revenue recognition for the year ended December 31, 2020.

The Organization uses the practical expedient to record revenue as if there is no significant financing component when the receivable is due within one year.

Note 13 - Retirement Plan

The Organization maintains a tax-sheltered retirement plan qualified under Internal Revenue Code Section 403(b). Under this plan, a qualified participant can elect to have 3.5% of compensation withheld for payment into a pension plan. In addition, the Organization contributes a matching percentage of no more than 7% of the compensation of participating employees to the plan. The Organization's contributions to the plan for the years ended December 31, 2020 and 2019, were \$514,447 and \$510,338, respectively.

Note 14 - Operating Leases

The Organization leases office space in Connecticut, Illinois, Indiana, New Jersey, Ohio and Korea, and various equipment under agreements that expire through 2023.

The following is a schedule of future minimum rental payments for the years ending December 31, 2020:

<u>Year Ending December 31,</u>	
2021	\$ 360,517
2022	229,631
2023	<u>49,997</u>
Total	<u>\$ 640,145</u>

Total rent expense for the years ended December 31, 2020 and 2019 was \$627,211 and \$738,543, respectively.

Rental expense is recorded on the straight line basis, while actual rental payments per the lease agreements are not straight-line. Some of the leases have an initial period of no rent or very low rent, and then rent payments gradually increase over the term of the lease. The deferred rent on the statement of financial position represents the accumulated difference between the straight-line rent expense and actual rent payments.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 15 - Net Assets Release from Restrictions

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose or by occurrence of the passage of time or other events specified by the donors as follows for the year ended December 31:

	<u>2020</u>	<u>2019</u>
Satisfaction of purpose restrictions		
Gift of Sight	\$ 40,949	\$ 41,100
Charitable purposes	12,700	14,121
Education programs	24,186	35,814
Research programs	-	100,888
Scholarships	-	6,960
Building fund	-	5,000
Equipment fund	26,138	18,468
Pakistan Eye Bank	-	102,000
	<u>\$ 103,973</u>	<u>\$ 324,351</u>

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 16 - Net Assets with Donor Restrictions

Net assets with donor restrictions are restricted for the following purposes and periods at December 31:

	<u>2020</u>	<u>2019</u>
Subject to expenditure for specified purpose:		
Gift of Sight	\$ 27,650	\$ 35,600
Charitable purposes	6,000	-
Education programs	-	24,186
Scholarships	28,697	28,597
Equipment fund	23,999	50,136
Pakistan Eye Bank	<u>20,000</u>	<u>20,000</u>
	<u>106,346</u>	<u>158,519</u>
Endowments (perpetual in nature):		
Subject to NFP endowment spending policy and appropriation		
Beverly A. Blettner Community Education	6,550	6,550
Gift of Hope and Vision Research	54,483	54,483
Gift of Sight Charitable	<u>30,920</u>	<u>30,920</u>
Total endowments	<u>91,953</u>	<u>91,953</u>
Total net assets with donor restrictions	<u><u>\$ 198,299</u></u>	<u><u>\$ 250,472</u></u>

During the year ended June 30, 2007, the Organization created the Beverly A. Blettner Community Education Endowment Fund. The donors stipulated that the principal amount may not be expended. The income generated from the principal may be used for educational purposes.

During the year ended June 30, 2005, the Organization created the Gift of Hope and Vision Research Endowment Fund. The donors stipulated that the principal amounts of \$25,000 and \$30,000 may not be expended. The income generated from the principal may be used to provide for annual distributions to support Eversight Gift of Hope Eye and Vision Research Program.

During the year ended June 30, 2005, the Organization created the Gift of Sight Charitable Endowment Fund. The donor stipulated that the \$385 principal may not be expended. The income generated from the principal may be used to waive or reduce tissue processing fees for patients who are unable to pay.

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

Note 17 - Research and Training Tissues (Unaudited)

During the years ended December 31, 2020 and 2019, the Organization supplied 2,644 and 2,137, research tissues to medical facilities and universities for research and training purposes. Estimated costs to procure these tissues are included in research program expenditures.

Note 18 - Fair Value Measurements

Fair value is defined as the amount that would be received from the sale of an asset or paid for the transfer of a liability in an orderly transaction between market participants, i.e. an exit price. To estimate an exit price, a three-tier hierarchy is used to prioritize the inputs:

Level 1: Quoted prices in active markets for identical securities

Level 2: Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment spreads, credit risk, etc.).

Level 3: Significant unobservable inputs (including the Organization's own assumptions in determining the fair value of investments).

The inputs and methodology used for valuing the Organization's financial assets and liabilities are not indicators of the risks associated with those instruments.

The following tables provide fair value measurement information of marketable debt and equity securities measured at fair value as of December 31, 2020 and 2019:

	Balance at December 31, 2020	Quoted prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)
Money market funds	\$ 1,574,861	\$ 1,574,861	\$ -
Debt securities of the U.S. Treasury and other U.S. government corporations and agencies	1,263,809	-	1,263,809
Municipal bonds	740,776	740,776	-
Corporate bonds	752,899	752,899	-
Other fixed income	293,891	293,891	-
Equity securities	4,844,118	4,844,118	-
	<u> </u>	<u> </u>	<u> </u>
Total assets at fair value	<u>\$ 9,470,354</u>	<u>\$ 8,206,545</u>	<u>\$ 1,263,809</u>

Eversight and Subsidiary
Notes to the Consolidated Financial Statements
December 31, 2020
(With Summarized Comparative Information for 2019)

	Balance at December 31, 2019	Quoted prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)
Money market funds	\$ 146,130	\$ 146,130	\$ -
Debt securities of the U.S. Treasury and other U.S. government corporations and agencies	1,110,951	-	1,110,951
Municipal bonds	572,384	572,384	-
Corporate bonds	970,000	970,000	-
Other fixed income	1,134,462	1,134,462	-
Equity securities	2,831,345	2,831,345	-
	<u>6,765,272</u>	<u>5,654,321</u>	<u>1,110,951</u>
Total assets at fair value	\$ <u>6,765,272</u>	\$ <u>5,654,321</u>	\$ <u>1,110,951</u>

Fair values for investments are determined by reference to quoted market prices and other relevant information generated by market transactions. There have been no changes in the methodologies used to determine fair value.

Note 19 - Self-Insurance

The Organization is self-funded for vision, dental, and health benefits. Employees who elect coverage agree to a copayment. Medical benefits are insured with Blue Cross in a high deductible plan and supplemented by the Organization. Management believes they have adequately provided for all claims incurred in the accompanying financial statements.

Changes in balances of claims liabilities, which are included in the accrued liabilities, for the year ended December 31, 2020 is as follows:

Unpaid claims, December 31, 2019	\$ 82,327
Incurred claims	1,017,275
Claim payments	<u>(1,042,202)</u>
Unpaid claims, December 31, 2020	<u>\$ 57,400</u>

Note 20 - COVID-19 Pandemic

As result of the global coronavirus pandemic of 2020, many organizations' financial picture has seen an unanticipated change. The duration and full effects of the outbreak are currently unknown, as the global picture continues to change daily. While management is hopeful that the impact is temporary in nature, it is not possible to estimate the effect this may have on the Company. Accordingly, no adjustments to the consolidated financial statements were made as a result of this ongoing event.

Supplementary Information

Eversight and Subsidiary
Consolidating Statement of Financial Position
December 31, 2020

	Eversight	Eversight International	Eliminations	Total
Assets				
Current Assets				
Cash and cash equivalents	\$ 4,492,241	\$ 444,196	\$ -	\$ 4,936,437
Accounts receivables	3,061,620	343,118	-	3,404,738
Unconditional pledges to give	10,000	-	-	10,000
Intercompany receivable	11,902,009	11,599,103	(23,501,112)	-
Prepaid expenses	84,373	1,667	-	86,040
Total current assets	19,550,243	12,388,084	(23,501,112)	8,437,215
Deposits	161,271	20,902	-	182,173
Unconditional pledges to give, net of current portion	10,000	-	-	10,000
Investments	9,470,354	-	-	9,470,354
Property and equipment, net	7,590,869	-	-	7,590,869
Total assets	\$ 36,782,737	\$ 12,408,986	\$ (23,501,112)	\$ 25,690,611
Liabilities and Net Assets				
Current Liabilities				
Accounts payable	\$ 668,758	\$ -	\$ -	\$ 668,758
Deferred revenue	-	9,897	-	9,897
Intercompany payable	11,599,103	11,902,009	(23,501,112)	-
Current portion of mortgage payable	2,246,600	-	-	2,246,600
Capital lease obligation, current portion	340,861	-	-	340,861
Accrued liabilities	800,393	318,240	-	1,118,633
Total current liabilities	15,655,715	12,230,146	(23,501,112)	4,384,749
Capital lease obligation, net of current portion	6,760,652	-	-	6,760,652
Deferred rent	34,333	-	-	34,333
Total liabilities	22,450,700	12,230,146	(23,501,112)	11,179,734
Net assets				
Without donor restrictions				
Undesignated	4,300,627	158,840	-	4,459,467
Board designated capital reserve	474,711	-	-	474,711
Board designated endowments	87,134	-	-	87,134
Board designated scholarships	100,000	-	-	100,000
Board designated investment fund	9,191,266	-	-	9,191,266
Total without donor restrictions	14,153,738	158,840	-	14,312,578
With donor restrictions				
Perpetual in nature	91,954	-	-	91,954
Purpose restrictions	86,345	20,000	-	106,345
Total with donor restrictions	178,299	20,000	-	198,299
Total net assets	14,332,037	178,840	-	14,510,877
Total liabilities and net assets	\$ 36,782,737	\$ 12,408,986	\$ (23,501,112)	\$ 25,690,611

Eversight and Subsidiary
Consolidating Statement of Activities
For the Year Ended December 31, 2020

	Eversight		Eversight International			Total		
	Without Donor Restrictions	With Donor Restrictions	Without Donor Restrictions	With Donor Restrictions	Eliminations	Without Donor Restriction	With Donor Restrictions	Total
Public support and program revenues								
Public support								
Contributions	\$ 648,657	\$ 51,800	\$ 5,756	\$ -	\$ -	\$ 654,413	\$ 51,800	\$ 706,213
Program service fee revenue								
Eye tissue processing fees	18,344,354	-	2,033,034	-	-	20,377,388	-	20,377,388
Other revenue	198,953	-	(106,867)	-	-	92,086	-	92,086
Intercompany charges	1,410,540	-	-	-	(1,410,540)	-	-	-
Total program revenues	19,953,847	-	1,926,167	-	(1,410,540)	20,469,474	-	20,469,474
Net assets released from restrictions	103,973	(103,973)	-	-	-	103,973	(103,973)	-
Total public support and program revenues	20,706,477	(52,173)	1,931,923	-	(1,410,540)	21,227,860	(52,173)	21,175,687
Expenses								
Program services								
Tissue procurement and processing program	14,278,099	-	1,785,100	-	(1,410,540)	14,652,659	-	14,652,659
Education program	138,367	-	-	-	-	138,367	-	138,367
Research program	1,036,072	-	25,013	-	-	1,061,085	-	1,061,085
Total program services	15,452,538	-	1,810,113	-	(1,410,540)	15,852,111	-	15,852,111
Support services								
Administration	4,316,075	-	71,665	-	-	4,387,740	-	4,387,740
Fundraising	648,007	-	-	-	-	648,007	-	648,007
Total support services	4,964,082	-	71,665	-	-	5,035,747	-	5,035,747
Total expenses	20,416,620	-	1,881,778	-	(1,410,540)	20,887,858	-	20,887,858
Program net income (loss)	289,857	(52,173)	50,145	-	-	340,002	(52,173)	287,829
Nonoperating income								
Net investment earnings	1,001,094	-	-	-	-	1,001,094	-	1,001,094
Change in net assets	1,290,951	(52,173)	50,145	-	-	1,341,096	(52,173)	1,288,923
Net assets - beginning of year	12,862,787	230,472	108,695	20,000	-	12,971,482	250,472	13,221,954
Net assets - end of year	\$ 14,153,738	\$ 178,299	\$ 158,840	\$ 20,000	\$ -	\$ 14,312,578	\$ 198,299	\$ 14,510,877